This case highlights the potential of combining a DPP-4 inhibitor (sitagliptin) with an SGLT2 inhibitor (empagliflozin), which may help improve glycemic control in a patient with CMT complicated by type 2 diabetes and appears not to have compromised skeletal muscle mass. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.